Designation of Arsenic Trioxide as an orphan drug - Phebra Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, establishes the regulatory framework for therapeutic goods in the country, addressing issues related to the safety, quality, and efficacy of these products. The Act was introduced to ensure that therapeutic goods available in Australia meet appropriate standards, and to facilitate the regulation of such goods to protect public health. As part of its regulatory function, the Therapeutic Goods Administration, under the authority granted by the Act, can designate certain drugs as orphan drugs. This designation is intended to encourage the research, development, and availability of treatments for rare diseases or conditions that affect a small number of people. The designation of Arsenic Trioxide as an orphan drug for the treatment of Acute Promyelocytic Leukaemia on 16 March 2017 exemplifies this objective, recognising the need for specialised treatments for rare medical conditions and supporting the efforts of sponsors like Phebra Pty Ltd in bringing such therapies to market.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Commonwealth of Australia, designates arsenic trioxide as an orphan drug specifically for the treatment of Acute Promyelocytic Leukaemia (APL). This designation, which applies to arsenic trioxide in its capsule dose form, is effective as of 16 March 2017. The orphan drug status is granted to encourage the development and availability of treatments for rare conditions that affect a small number of people, in this case, APL. The Act applies to the sponsor of the drug, in this instance, Phebra Pty Ltd, which is responsible for the drug's development, registration, and compliance with therapeutic goods standards. The geographic reach of this legislation is national, extending throughout the Commonwealth of Australia. The orphan drug designation does not exclude any particular persons, entities, or industries but is limited to the specified drug and indication. The designation is made under the authority of the Therapeutic Goods Regulations 1990, and any further details or conditions pertaining to the application, approval, or use of arsenic trioxide as an orphan drug would be governed by these regulations and any subordinate instruments issued under the Act.

Key Provisions

The Therapeutic Goods (Orphan Drugs) Designation 2017, issued under section 16J of the Therapeutic Goods Regulations 1990, designates Arsenic Trioxide as an orphan drug for the treatment of Acute Promyelocytic Leukaemia (APL) (section 1). This designation is effective from 16 March 2017 and specifies that the relevant dose form for this indication is in the form of capsules. The sponsor of the therapeutic good, Arsenic Trioxide, is identified as Phebra Pty Ltd. The obligations placed upon the parties involved in this legislation are primarily concerned with the sponsorship and use of Arsenic Trioxide for the designated orphan drug indication. The sponsor, Phebra Pty Ltd, must ensure that the therapeutic good is manufactured and supplied in accordance with the requirements set forth by the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. This includes maintaining appropriate quality, safety, and efficacy standards, as well as providing accurate and comprehensive information about the therapeutic good. Failure to comply with the provisions of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 may result in various civil and criminal consequences. Under section 15 of the Therapeutic Goods Act 1989, a person who contravenes the Act may be subject to civil penalty proceedings, which can result in fines of up to $222,200 for individuals and $1,111,000 for bodies corporate. Additionally, under section 35 of the Therapeutic Goods Act 1989, a person who contravenes certain provisions of the Act may be subject to criminal prosecution and, if convicted, may be subject to penalties including imprisonment for up to five years and/or substantial fines. It is important for all parties involved to be aware of these potential consequences and to ensure compliance with the relevant legislative requirements.